- Palladium-Catalyzed Dehydrogenative Fluoroalkoxylation of Benzaldehydes
-
A direct and efficient palladium-catalyzed oxidative dehydrogenative fluoroalkoxylation of benzaldehydes is reported here for the first time. The method features mild reaction conditions, good tolerance of functional groups, and a broad substrate scope. The protocol employs the transient directing group strategy, thereby avoiding the additional installation and removal of directing groups, endowing the method with great advantages of atom and step economy. The approach should find broad applications in drug synthesis and discovery processes.
- Jin, Long,Zhang, Xing-Long,Guo, Rui-Li,Wang, Meng-Yue,Gao, Ya-Ru,Wang, Yong-Qiang
-
-
Read Online
- ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND
-
Disclosed is an antitumor effect potentiator for one or more other compounds having an antitumor effect, the antitumor effect potentiator comprising a novel pyrrolopyrimidine compound.
- -
-
Paragraph 0340; 0356
(2018/11/21)
-
- NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT
-
An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.
- -
-
Paragraph 0438; 0439; 0471; 0472
(2017/03/28)
-
- BENZISOXAZOLE DERIVATIVES
-
This invention relates to compounds of the formula (I): wherein A, B, R1, R4, m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
- -
-
Page/Page column 102-103
(2008/06/13)
-